Last update 21 Nov 2024

Befotertinib Mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Befotertinib
+ [2]
Mechanism
EGFR T790M inhibitors(EGFR T790M inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure

Molecular FormulaC30H36F3N7O5S
InChIKeyFFQDXZLQXPZZDJ-UHFFFAOYSA-N
CAS Registry2226167-02-6

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer
CN
28 Sep 2023
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer
CN
28 Sep 2023
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma
CN
29 May 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR positive non-small cell lung cancerPhase 3
CN
22 Mar 2023
metastatic non-small cell lung cancerPhase 3
CN
24 Dec 2019
EGFR Mutation Lung CancerPhase 2
CN
12 Aug 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 2
CN
28 Feb 2019
EGFR-mutated non-small Cell Lung CancerPhase 1
CN
01 Sep 2023
EGFR T790M Mutation Positive Non-Small Cell Lung CarcinomaPhase 1
CN
04 Jan 2018
Advanced Lung Non-Small Cell CarcinomaDiscovery
CN
03 Jan 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
362
(ezqccfztao) = exwkojjuyy znwmnndrgw (nglqpgwxkq )
Superior
02 Dec 2022
(ezqccfztao) = ntwxczrgnt znwmnndrgw (nglqpgwxkq )
Phase 2
Second line
-
(jncodhzqxa) = smpesddotv yzvxxlsmqw (idlslhocad, 46.3% - 61.5%)
-
06 Aug 2022
(jncodhzqxa) = gvhphosult yzvxxlsmqw (idlslhocad, 60.1% - 71.3%)
Phase 2
-
(lvggikicft) = jtteesnabs mkicpouoae (wszuxyptej, 46.3% - 61.5%)
Positive
17 Jun 2022
(lvggikicft) = brzxnhszyt mkicpouoae (wszuxyptej, 61.9% - 72.9%)
Phase 1
84
(pmytboiwkk) = drvifpdfed kuzjkcvdhb (eiosasfphm )
Positive
11 Mar 2022
Phase 2
290
(mexujgueoa) = hulsdjrmje qfuefptxpw (gngkatvkde, 43.5 - 58.7)
-
01 Jul 2021
(mexujgueoa) = wtettnrvjt qfuefptxpw (gngkatvkde, 59.0 - 70.3)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free